Skip to Content

Agenus Inc AGEN

Morningstar Rating
$10.86 +0.36 (3.43%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AGEN is trading at a 653% premium.
Price
$10.89
Fair Value
$96.37
Uncertainty
Extreme
1-Star Price
$34.28
5-Star Price
$8.66
Economic Moat
Kzjhs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AGEN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$10.50
Day Range
$10.3011.41
52-Week Range
$4.7842.60
Bid/Ask
$10.63 / $10.88
Market Cap
$228.05 Mil
Volume/Avg
430,354 / 757,331

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.21
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
389

Comparables

Valuation

Metric
AGEN
XNCR
STRO
Price/Earnings (Normalized)
Price/Book Value
2.322.55
Price/Sales
1.218.641.58
Price/Cash Flow
Price/Earnings
AGEN
XNCR
STRO

Financial Strength

Metric
AGEN
XNCR
STRO
Quick Ratio
0.216.874.33
Current Ratio
0.247.084.46
Interest Coverage
−1.26−2.75
Quick Ratio
AGEN
XNCR
STRO

Profitability

Metric
AGEN
XNCR
STRO
Return on Assets (Normalized)
−63.60%−9.88%−26.19%
Return on Equity (Normalized)
−12.51%−79.63%
Return on Invested Capital (Normalized)
−13.81%−56.43%
Return on Assets
AGEN
XNCR
STRO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJknddxqzRzffd$586.1 Bil
VRTX
Vertex Pharmaceuticals IncQfpvwwdfLmxvm$113.7 Bil
REGN
Regeneron Pharmaceuticals IncVhxfmdhDxgsnnc$108.2 Bil
MRNA
Moderna IncYfvqypsskXkd$50.9 Bil
ARGX
argenx SE ADRSyvnhlqtKdcsb$22.0 Bil
BNTX
BioNTech SE ADRBgpdpvqcCgyvt$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncVpwsqslwScjscwf$18.9 Bil
BMRN
Biomarin Pharmaceutical IncDyqcwcnKfnqcj$14.6 Bil
INCY
Incyte CorpLmgqsrfbDshssfn$12.8 Bil
RPRX
Royalty Pharma PLC Class AZfygqzkphVkzccn$12.3 Bil

Sponsor Center